Panagora Asset Management’s Oruka Therapeutics ORKA Stock Holding History

Panagora Asset Management’s Portfolio ORKA Stock Details ORKA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-573	Closed	-$28K	–	2942
2020 Q4	$28K	Buy	+573	New	+$28.5K	﹤0.01%	2144
2019 Q1	–	Sell	-386	Closed	-$28K	–	2584
2018 Q4	$28K	Sell	386 -7	-2%	-$868	﹤0.01%	2141
2018 Q3	$48K	Sell	393 -19	-5%	-$2.45K	﹤0.01%	2029
2018 Q2	$49K	Hold	412	–	–	﹤0.01%	2044
2018 Q1	$44K	Buy	412 +224	+119%	+$60.1K	﹤0.01%	2075
2017 Q4	$56K	Buy	+188	New	+$54.4K	﹤0.01%	2031
2016 Q3	–	Sell	-358	Closed	-$224K	–	2466
2016 Q2	$224K	Buy	+358	New	+$265K	﹤0.01%	1631

Other funds holding ORKA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return

Panagora Asset Management's ORKA Position: Q1 2021 in Review

Panagora Asset Management sold out of Oruka Therapeutics (ORKA) in Q1 2021, closing a stake of 573 shares — an estimated $28K sold.

Panagora Asset Management first reported a position in ORKA in Q2 2016 and held it in 7 quarters. The position peaked at $224K in Q2 2016. 17 funds tracked by Wall St. Rank hold ORKA as of Q1 2021.

Panagora Asset Management reported no remaining Oruka Therapeutics position as of Q1 2021 after selling out during the quarter.
Panagora Asset Management sold 573 Oruka Therapeutics shares in Q1 2021, an estimated $28K.
Panagora Asset Management first reported a position in Oruka Therapeutics in Q2 2016 and held it in 7 quarters.
Panagora Asset Management's Oruka Therapeutics position peaked at $224K in Q2 2016.
17 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q1 2021.

Based on Panagora Asset Management's 13F filing for Q1 2021, filed 12 May 2021.